AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04743934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually identical placebo tablets taken by mouth daily at bedine
Trial: NCT04743934
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
Trial: NCT05286554
Drug: gonadotropin releasing hormone-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT05324462
Drug: IDegLira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
Trial: NCT05764265
Drug: LTP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTP001 will be administered orally once daily in the morning
Trial: NCT06166992
Drug: [14C]-BI 1291583
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-BI 1291583
Trial: NCT05992883
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
Trial: NCT05322707
Drug: Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol
RxNorm normalized name: Symbicort, 80 mcg-4.5 mcg/inh inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aerosol, 2 actuations orally inhaled twice daily
Trial: NCT05322707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aerosol, 2 actuations orally inhaled twice daily
Trial: NCT05253833
Drug: AR882 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Oral Capsule
Trial: NCT05253833
Drug: AR882 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Oral Capsule
Trial: NCT04564898
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days
Trial: NCT04564898
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days
Trial: NCT06752382
Drug: Experimental drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.
Trial: NCT06751914
Drug: Neoantigen-based peptide vaccine
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Trial: NCT05947955
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration in the same volume as the active therapy
Trial: NCT06528444
Drug: Grup 1 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1 capsule (6 mg) /day for 7 days.
Trial: NCT05090124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
Trial: NCT04923542
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
Trial: NCT06250205
Drug: Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT06250205
Drug: Drospirenone / Ethinyl Estradiol (COC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT05133297
Drug: TLL-018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at dose1 BID daily for 24 weeks.
Trial: NCT05133297
Drug: TLL-018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at dose2 BID daily for 24 weeks.
Trial: NCT05133297
Drug: TLL-018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at dose3 BID daily for 24 weeks.
Trial: NCT04836429
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo photodynamic therapy
Trial: NCT05790707
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
Trial: NCT05400967
Drug: 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
Trial: NCT05743621
Drug: TVB-2640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
Trial: NCT05554939
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Trial: NCT06791577
Drug: Carboxytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of the intervention (CO2 Lift) in the area according to the protocol schedule
Trial: NCT05809908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose of IMP will be administered orally 30 minutes after completing a meal.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of safflower oil; 80 ml total daily dose of placebo, over the course of 3 weeks.
Trial: NCT04760613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical capsules containing placebo (taken daily by mouth)
Trial: NCT06785740
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin use
Trial: NCT06206564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
Trial: NCT06785974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Placebo in combination with ICI-therapy
Trial: NCT04699188
Drug: JDQ443
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRAS G12C inhibitor
Trial: NCT05922878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule QD
Trial: NCT06627231
Drug: TEV-56286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT06627231
Drug: [14C]-TEV-56286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT05150795
Drug: Fentanyl 100 micrograms ampoule
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
Trial: NCT06566833
Drug: self assmbling peptide p11-4 combined with 0.05% fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biomimetic remineralizing agent
Trial: NCT05099172
Drug: BAY2927088_formulation B_1
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05099172
Drug: BAY2927088_formulation B_2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06161519
Drug: PLX038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle
Trial: NCT05479812
Drug: WTX-124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigation Product Monotherapy
Trial: NCT05178810
Drug: FAB122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose 100 mg
Trial: NCT05178810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose
Trial: NCT06253520
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Trial: NCT04935320
Drug: HTL0016878.HCl Solution 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution fasted
Trial: NCT04935320
Drug: HTL0016878.Citrate Capsule 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule fed or fasted
Trial: NCT05220514
Drug: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Trial: NCT06539741
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Trial: NCT06539741
Drug: Acetaminophen 500mg
RxNorm normalized name: ACETAMINOPHEN 500MG CAP
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Trial: NCT04899115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
Trial: NCT06262919
Drug: Tafinlar/Mekinist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
Trial: NCT05769660
Drug: BEY1107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer twice daily, PO, 4-week continuous dose.
Trial: NCT06332599
Drug: PBM4M4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg four times a day, and metronidazole 400 mg four times a day
Trial: NCT06332599
Drug: PBM3M3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg three times a day, and metronidazole 400 mg three times a day
Trial: NCT06332599
Drug: PBM2M4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg four times a day
Trial: NCT06332599
Drug: PBM2M3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI（esomeprazole or vonoprazan), bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg three times a day
Trial: NCT05632159
Drug: conventional anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
Trial: NCT05026593
Drug: IBI110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI110 RP2D will be administered by IV infusion on Day 1 of each 21-day .
Trial: NCT04823611
Drug: Part A:Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT04823611
Drug: Part A:AZD8233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Trial: NCT04823611
Drug: Part B:Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT04823611
Drug: Part B:AZD8233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Trial: NCT04823611
Drug: Part C: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT04823611
Drug: Part C: AZD8233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Trial: NCT04927195
Drug: EDP1867
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Trial: NCT04927195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT05417646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator to empagliflozin
Trial: NCT05704361
Drug: RO7121932 - MAD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 3: Participants will receive multiple doses of RO7121932 administered as SC injections.
Trial: NCT04827953
Drug: NLM-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLM-001 will be administered three cycles consecutively followed by two rest cycles.
Trial: NCT06789796
Drug: QL1604
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, every 3 weeks
Trial: NCT06789796
Drug: placebo for Iparomlimab and Tuvonralimab (QL1706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 3 weeks
Trial: NCT06628908
Drug: Placebo (matched to SUZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to SUZ for oral administration.
Trial: NCT06628908
Drug: Placebo (matched to Pregabalin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Pregabalin for oral administration.
Trial: NCT04771156
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
Trial: NCT04771156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
Trial: NCT04745299
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months
Trial: NCT05750966
Drug: cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
Trial: NCT05750966
Drug: cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
Trial: NCT06101784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
Trial: NCT06158126
Drug: Initiating daily oral PrEP during pregnancy
RxNorm normalized name: Daily Hist Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1a will include pregnant women who initiate oral PrEP when already pregnant, at enrollment into the study.
Trial: NCT05722860
Drug: L-Citrulline, capsule
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5g/daily dose for the duration of 1 week intervention
Trial: NCT06301997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied twice daily for 3 weeks after enrolment
Trial: NCT06772441
Drug: Androgen deprivation therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Goserelin: AstraZeneca, 10.8mg injection~* ADT will be applied for 12 months in total~* ADT must be given concurrently and adjuvant
Trial: NCT05138757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
Trial: NCT06444529
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle
Trial: NCT05707897
Drug: TS-142 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of 10 mg of TS-142
Trial: NCT05842174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
Trial: NCT04474847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
Trial: NCT04795856
Drug: [11C] acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET Tracer
Trial: NCT04963296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
Trial: NCT04963296
Drug: Acetaminophen/Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Trial: NCT05717621
Drug: VTD-101 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of VTD-101 ointment (Decitabine ointment)
Trial: NCT00002276
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05561725
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014.
Trial: NCT05438329
Drug: DB-1305/BNT325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Injection of Vein (I.V.)
Trial: NCT05438329
Drug: BNT327
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered I.V.
Trial: NCT06794996
Drug: Inaxaplin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for Oral Administration.
Trial: NCT05358938
Drug: Checkpoint Blockade, Immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
Trial: NCT06794710
Drug: diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive pharmacological treatment for heart failure.
Trial: NCT05548426
Drug: Group A, Penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Trial: NCT05930938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xevinapant without active substance